title: Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer.
abstract: This phase II study evaluated the activity of gemcitabine (Gemzar) plus cisplatin (Platinol) as first-line treatment of advanced epithelial ovarian cancer. Forty-two chemonaive patients with advanced (stage III and IV) epithelial ovarian cancer received gemcitabine 1,250 mg/m(2) on days 1 and 8 and cisplatin 100 mg/m(2) on day 1, every 3 weeks, up to eight cycles. The median number of cycles completed was 5 (range 2-8). Of the 41 patients evaluable for tumor response, 20 had a partial response and nine had a complete response, for an overall clinical and pathologic response rate of 70.7% (95% CI 56.8-84.6%). Median overall survival for all 42 patients was 23.4 months (95% CI 15.9-29.9 months) and the median progression-free survival time was 10.4 months (95% CI 9.4-13.5 months). The combination was generally manageable. Hematologic toxicity (grade 3/4 neutropenia: 31.0/21.4%; grade 3/4 thrombocytopenia: 9.5/4.8%; grade 3/4 anemia: 11.9/0%) and nausea and vomiting (grade 3/4: 35.7/31.0%) were the most common toxicities. There was one toxic death (septic shock due to hematologic toxicity-induced infection). We conclude that gemcitabine plus cisplatin is active and feasible as first-line treatment of advanced epithelial ovarian cancer. Further clinical trials with the addition of gemcitabine to first-line treatment appear warranted.
authors.affiliation: Consorci Hospitalari del Parc Tauli, 08208 Sabadell, Spain. mnogue@cspt.es
authors.forename: Miquel
authors.initials: M
authors.lastname: Nogué
authors.forename: Lluis
authors.initials: L
authors.lastname: Cirera
authors.forename: Angels
authors.initials: A
authors.lastname: Arcusa
authors.forename: Eduard
authors.initials: E
authors.lastname: Batiste-Alentorn
authors.forename: Anna
authors.initials: A
authors.lastname: Balil
authors.forename: Albert
authors.initials: A
authors.lastname: Font
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Perez-Gracia
authors.forename: Eva Maria
authors.initials: EM
authors.lastname: Carrasco
authors.forename: Ignasi
authors.initials: I
authors.lastname: Tusquets
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D002945:Cisplatin; D000093542:Gemcitabine